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Abstract
Background: Postmenopausal hormone therapy (HT) is associated with a decreased colorectal cancer (CRC) risk. As CRC is a
heterogeneous disease, we evaluated whether the association of HT and CRC differs across etiologically relevant, molecularly
defined tumor subtypes and tumor location. Methods: We pooled data on tumor subtypes (microsatellite instability status,
CpG island methylator phenotype status, BRAF and KRAS mutations, pathway: adenoma-carcinoma, alternate, serrated), tu-
mor location (proximal colon, distal colon, rectum), and HT use among 8220 postmenopausal women (3898 CRC cases and
4322 controls) from 8 observational studies. We used multinomial logistic regression to estimate odds ratios (OR) and 95%
confidence intervals (CIs) for the association of ever vs never HT use with each tumor subtype compared with controls.
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Models were adjusted for study, age, body mass index, smoking status, and CRC family history. All statistical tests were 2-
sided. Results: Among postmenopausal women, ever HT use was associated with a 38% reduction in overall CRC risk (OR
¼0.62, 95% CI ¼ 0.56 to 0.69). This association was similar according to microsatellite instability, CpG island methylator
phenotype and BRAF or KRAS status. However, the association was attenuated for tumors arising through the serrated
pathway (OR ¼ 0.81, 95% CI ¼ 0.66 to 1.01) compared with the adenoma-carcinoma pathway (OR ¼ 0.63, 95% CI ¼ 0.55 to 0.73;
Phet ¼.04) and alternate pathway (OR ¼ 0.61, 95% CI ¼ 0.51 to 0.72). Additionally, proximal colon tumors had a weaker associa-
tion (OR ¼ 0.71, 95% CI ¼ 0.62 to 0.80) compared with rectal (OR ¼ 0.54, 95% CI ¼ 0.46 to 0.63) and distal colon (OR ¼ 0.57, 95%
CI ¼ 0.49 to 0.66; Phet ¼.01) tumors. Conclusions: We observed a strong inverse association between HT use and overall CRC
risk, which may predominantly reflect a benefit of HT use for tumors arising through the adenoma-carcinoma and alternate
pathways as well as distal colon and rectal tumors.
Colorectal cancer (CRC) is a heterogeneous disease that evolves
through multiple pathways defined by genetic and epigenetic
events (1, 2). Four tumor markers have been commonly used to
better characterize this heterogeneity: microsatellite instability
(MSI), CpG island methylator phenotype (CIMP), somatic muta-
tions in BRAF, and somatic mutations in KRAS. Together, these
tumor markers approximate 3 distinct molecular pathways of
colorectal carcinogenesis: adenoma-carcinoma (traditional), al-
ternate, and serrated (1, 3, 4). These pathways are established
early in disease pathogenesis and can be identified within pre-
cancerous lesions by microscopy (3, 5–8). Research has shown
that these tumor types have distinct appearances, predilections
for locations within the colon, and biologic behaviors (8–10). As
such, it is plausible that the epidemiologic factors underlying
their etiologies could also differ.
Multiple lines of evidence, including randomized controlled
trials, show that postmenopausal hormone therapy (HT) is as-
sociated with a decreased risk of CRC (11–20). The reduction in
risk, about 20%–40% in recent analyses, has been observed in
users of estrogen alone as well as combined estrogen plus pro-
gestin. Few studies have evaluated whether the association of
HT use and CRC risk differs by molecularly defined CRC sub-
types; however, such information might increase the under-
standing of the mechanisms for this beneficial effect. Current
literature suggests that HT use is associated with a lower risk of
MSI-low or microsatellite stable tumors (MSI-L/MSS) and possi-
bly with a lower risk of CIMP-negative and BRAF wild-type
tumors (21, 22). HT use has only been associated with KRAS
wild-type tumors in the distal colon in 1 previous study (23).
Regarding tumor location, the association of HT use and CRC is
reportedly stronger among tumors of the distal colon compared
with the proximal colon (22, 24). To our knowledge, no study
has evaluated both tumor markers and location in relation to
HT use to provide a comprehensive understanding of subtype-
specific CRC risk.
In this study, we examined HT use in relation to molecularly
defined CRC subtypes using available data from the Colon
Cancer Family Registry (CCFR) (21, 25, 26) and 7 studies contrib-
uting to the Genetics of Epidemiology of Colorectal Cancer
Consortium (27, 28). Specifically, we evaluated each of the 4
common tumor markers (MSI, CIMP, BRAF, and KRAS) sepa-
rately, as well as 3 pathways of carcinogenesis defined by com-
binations of those markers and tumor location.
Methods
Study Populations
Data from 8 observational studies of CRC were pooled: the
Cancer Prevention Study II (CPS-II) (29), the German Darmkrebs:
Chancen der Verhutung durch Screening Study (DACHS) (30, 31),
the Diet Activity and Lifestyle Study (DALS) (32), the Swedish
population of the European Prospective Investigation into
Cancer (EPIC) (33), the Melbourne Collaborative Cohort Study
(MCCS) (34), the Nurses’ Health Study (NHS) (35, 36), the
Northern Sweden Health and Disease Study (NSHDS) (37), and 3
population-based sites from the Colon Cancer Family Registry
(21, 25, 26). Each study included women diagnosed with incident
invasive CRC and contemporaneous unaffected controls. Only
women with tumor marker data were eligible for inclusion in
this analysis. Study-specific details are described in the
Supplementary Methods (available online). All participants pro-
vided informed consent for participating in this research, and
studies were approved by their respective Institutional Review
Boards.
Data Collection and Harmonization
The harmonization procedure and ascertainment of HT use are
described in more detail in the Supplementary Methods (avail-
able online). Information on demographics and environmental
risk factors was collected via telephone or in-person interviews
and/or structured self-completed questionnaires (24, 38, 39). HT
use was generally ascertained as any self-reported use at base-
line survey. Additionally, ever use of formulation-specific (es-
trogen-only or estrogen plus progestin) HT use was derived
from 3 studies (CCFR, CPSII, and NHS). HT nonusers at reference
time were used as the comparison group. Postmenopausal sta-
tus was harmonized as either 1) study-derived menopausal sta-
tus, if available; 2) self-reported menopausal status, if study-
derived data were not available; or 3) age 55 years and older, if
study-derived and self-reported data were not available (40).
Tumor Characteristics and Molecular Subtyping
Tumor marker testing was conducted using DNA extracted
from formalin-fixed, paraffin-embedded tumor tissue speci-
mens. Individual study protocols varied, as outlined below and
further detailed in the Supplementary Methods (available
online).
MSI testing was primarily conducted using polymerase chain
reaction (PCR) following the National Cancer Institute Bethesda
Consensus Panel (CCFR, CPS-II, MCCS, NHS) (41). Typically, 4 or
more interpretable markers were required to classify tumors,
with some variation across studies outlined in Supplementary
Table 1 (available online). Additional methods used include im-
munohistochemistry (NSHDS, EPIC, and a subset of CCFR and
MCCS) and mononucleotide marker panels (DACHS, DALS)
(Supplementary Methods, available online). Tumors were classi-
fied as MSI-high (MSI-H) if at least 30% of the markers showed
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instability and MSI-L/MSS if less than 30% of the makers showed
instability. MSI status could be determined for 3639 CRC cases
(93.4%).
Most studies used Methylight (42) methylation analysis to
determine CIMP status, classified as positive or negative based
on either an 8- (CPS-II, EPIC, NHS, NSHDS) (43, 44) or 5-gene
(CCFR, MCCS) (45–47) panel. The percent of methylated refer-
ence value was calculated to determine whether each gene was
positive for methylation (generally percent of methylated refer-
ence > 10). DACHS used a different 5-gene panel (48, 49) to de-
termine CIMP status and based methylation on the presence or
absence of the methylation-specific PCR product. DALS (50) de-
termined CIMP status using a classic panel of CpG islands (51,
52). Specific genes included in each panel, details of calling
methylation status, and number of methylated genes present to
classify a tumor as CIMP-positive are outlined in
Supplementary Table 2 (available online). CIMP status could be
determined for 3453 CRC cases (88.6%).
Studies used PCR, sequencing, and immunohistochemistry
techniques to assess BRAF and KRAS mutations, as detailed in
the Supplementary Methods (available online). The majority of
studies evaluated BRAF via V600E mutations in exon 15 and
KRAS via mutations in codons 12 and 13, although a few evalu-
ated additional loci. BRAF and KRAS status could be determined
for 3564 (91.4%) and 3435 (88.1%) CRC cases, respectively.
Tumor pathways were defined as follows, consistent with
previously suggested classifications (3, 8): 1) Adenoma-
carcinoma (traditional) pathway (MSS/MSI-L, CIMP-negative,
BRAF wild-type, KRAS wild-type), 2) alternate pathway (MSS/
MSI-L, CIMP-negative, BRAF wild-type, KRAS-mutated), and 3)
serrated pathway (CIMP-positive, BRAF-mutated, KRAS wild-
type). Tumor pathway could be classified for 2401 CRC cases
(61.6%).
Tumor location was obtained from registry and pathology
reports. Location was grouped based on the International
Classification of Diseases (ICD-9) codes as follows: 1) Proximal
(153.0/Hepatic flexure, 153.1/Transverse colon, 153.4/Cecum,
153.6/Ascending colon), 2) distal (153.2/Descending colon, 152.3/
Sigmoid colon, 153.7/Splenic flexure), and 3) rectal (154.0/
Rectosigmoid junction, 154.1/Rectum). Tumor location could be
classified for 3808 CRC cases (97.7%).
Statistical Analysis
We excluded women who were pre- or perimenopausal at study
baseline (934 cases, 760 controls) and those with missing data
on HT use (208 cases, 209 controls). After exclusions, 3898 CRC
cases and 4322 controls were included in our analyses
(Figure 1).
Odds ratios (ORs) and 95% confidence intervals (CIs) from lo-
gistic regression models were used to approximate the relative
risks for the association of HT use and CRC. Separate models
were evaluated for each tumor-specific outcome using multino-
mial logistic regression with tumor marker status vs control as
the outcome (eg, BRAF-mutated or BRAF wild-type vs control).
All models included study site as well as covariates selected a
priori based on known associations with both HT and CRC.
Figure 1. Overview of participants included in analytic population. A-C ¼ adenoma-carcinoma; CIMP ¼ CpG island methylator phenotype; HT ¼ postmenopausal hor-
mone therapy; MSI ¼microsatellite instability. *Estrogen-only and estrogen plus progestin groups are not mutually exclusive.
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These included age in years, body mass index (BMI; normal or
underweight [BMI <25], overweight [BMI 25–30], obese [BMI
>30], unknown), smoking status (current, former, never, un-
known), and first-degree relative with CRC (yes, no, unknown).
Secondary analyses were conducted for estrogen-only therapy
and combined estrogen plus progestin therapy. For multinomial
logistic regression models, Wald v2 tests were used to evaluate
heterogeneity in odds ratios by tumor marker status (53).
Additionally, sensitivity analyses were conducted excluding
1) women aged 45 years and younger (n¼ 131) and 2) women
with probable Lynch syndrome based on 4 tumor markers (de-
fined as MSI-H, CIMP-negative, BRAF wild-type, KRAS wild-type;
n¼ 89), because both populations may have unique factors al-
tering their CRC risk. We also performed a meta-analysis of the
association of any HT use and CRC risk to evaluate heterogene-
ity by study site.
All analyses were conducted using R version 3.5.2 with a 2-
sided P less than .05 considered statistically significant.
Results
Baseline population characteristics of the 8220 postmenopausal
women in our study are shown in Table 1. Compared with
Table 1. Baseline characteristics of 8220 postmenopausal women by case-control status
Characteristicsa
Overall Case Control
(n¼ 8220) (n¼ 3898) (n¼ 4322)
Age, mean (SD), y 65.28 (9.08) 64.79 (9.54) 65.72 (8.62)
Age group, y
<45 101 (1.2) 84 (2.2) 17 (0.4)
45–55 828 (10.1) 464 (11.9) 364 (8.4)
55–65 2780 (33.8) 1246 (32.0) 1534 (35.5)
65–75 3309 (40.3) 1561 (40.0) 1748 (40.4)
>75 1202 (14.6) 543 (13.9) 659 (15.2)
First-degree relative with CRC
Yes 1251 (15.2) 722 (18.5) 529 (12.2)
No 6633 (80.7) 2994 (76.8) 3639 (84.2)
Missing 336 (4.1) 182 (4.7) 154 (3.6)
Body mass index
Normal or underweight 3659 (44.5) 1613 ( 41.4) 2046 (47.3)
Overweight 2818 (34.3) 1322 (33.9) 1496 (34.6)
Obese 1571 (19.1) 870 (22.3) 701 (16.2)
Missing 172 ( 2.1) 93 (2.4) 79 (1.8)
Smoking
Current smoker 948 (11.5) 522 (13.4) 426 (9.9)
Former smoker 2619 (31.9) 1285 (33.0) 1334 (30.9)
Never smoker 4477 (54.5) 2012 (51.6) 2465 (57.0)
Missing 176 (2.1) 79 (2.0) 97 (2.2)
Self-reported race
White 8077 (98.3) 3780 (97.0) 4297 (99.4)
Other 113 (1.4) 98 (2.5) 15 (0.4)
Missing 30 (0.4) 20 (0.5) 10 (0.2)
Study
CCFR 1985 (24.1) 1215 ( 31.2) 770 (17.8)
CPSII 893 (10.9) 412 ( 10.6) 481 (11.1)
DACHS 2074 (25.2) 872 ( 22.4) 1202 (27.8)
DALS 891 (10.8) 427 (11.0) 464 (10.7)
EPIC Sweden 129 (1.6) 37 (0.9) 92 (2.1)
MCCS 455 (5.5) 185 (4.7) 270 (6.2)
NHS 1649 (20.1) 686 (17.6) 963 (22.3)
NSHDS 144 (1.8) 64 (1.6) 80 (1.9)
Any postmenopausal hormone therapy use
Ever 3112 (37.9) 1262 (32.4) 1850 (42.8)
Never 5108 (62.1) 2636 (67.6) 2472 (57.2)
Estrogen-only
Ever 1160 (14.1) 506 (13.0) 654 (15.1)
Never 3323 (40.4) 1778 (45.6) 1545 (35.7)
Missing 3737 (45.5) 1614 (41.4) 2123 (49.1)
Estrogen plus progestin
Ever 717 (8.7) 328 (8.4) 389 (9.0)
Never 3758 (45.7) 1961 (50.3) 1797 (41.6)
Missing 3745 (45.6) 1609 (41.3) 2136 (49.4)
aNo. (%) shown unless otherwise indicated. CCFR ¼ Colon Cancer Family Registry; CPSII ¼ Cancer Prevention Study II; CRC ¼ colorectal cancer; DACHS ¼ Darmkrebs:
Chancen der Verhutung durch Screening Study; DALS ¼ Diet Activity and Lifestyle Study; EPIC ¼ European Prospective Investigation into Cancer; MCCS ¼ Melbourne
Collaborative Cohort Study; NHS ¼ Nurses’ Health Study; NSHDS ¼ Northern Sweden Health and Disease Study.
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controls, cases were more likely to have a family history of CRC
and be current or former smokers. Cases were less likely to be
HT users than controls (32.4% vs 42.8%). Among those with
formulation-specific data, cases were less likely than controls to
use both estrogen-only (22.2% vs 29.7%) and estrogen plus pro-
gestin formulations (14.3% vs 17.8%).
Multivariable-adjusted associations between HT use, HT for-
mulation, and overall- and tumor marker–specific CRC risk are
presented in Figure 2 and Supplementary Table 3 (available on-
line). Ever use of HT was associated with a 38% reduction in CRC
risk (OR¼ 0.62, 95% CI¼ 0.56 to 0.69). Both use of estrogen-only
(OR¼ 0.71, 95% CI¼ 0.62 to 0.83) and estrogen plus progestin
(OR¼ 0.76, 95% CI¼ 0.64 to 0.91) formulations were associated
with reduced CRC risk, although the effect estimates were at-
tenuated compared with any HT use in this subsample of the
study population. Few differences in baseline characteristics
were noted between women with and without formulation-
specific data (Supplementary Table 4, available online).
Among cases with respective tumor marker data, 19.8% were
MSI-H (n¼ 719), 24.3% were CIMP-positive (n¼ 841), 18.4% were
BRAF-mutated (n¼ 654), and 32.0% were KRAS-mutated
(n¼ 1098). Ever use of HT was associated with reduced risk of al-
most all tumor marker subtypes of CRC, with some variation
across subtypes (Figure 2; Supplementary Table 3, available on-
line). The association of ever HT use and CRC was attenuated
among CIMP-positive cases (OR¼ 0.74, 95% CI¼ 0.63 to 0.87)
compared with CIMP-negative cases (OR¼ 0.62, 95% CI¼ 0.55 to
0.69) (Phet ¼ .04). This trend was consistent across HT formula-
tions, although the difference in odds ratios was not statistically
significant. HT use was inversely associated with both KRAS-
mutated and wild-type individuals. This association was con-
sistent for estrogen-only use; however, estrogen plus progestin
formulations were not statistically significantly associated with
KRAS-mutated individuals (OR¼ 0.90, 95% CI¼ 0.70 to 1.14; Phet
¼ 0.09). No differences were observed for MSI or BRAF mutation
status.
Of 2401 tumors (61.6%) that were able to be classified by
pathway, the majority were classified as adenoma-carcinoma
pathway tumors (48.4%; n¼ 1162), with 32.9% classified as alter-
nate pathway (n¼ 790) and 18.7% as the serrated pathway
(n¼ 449). No major differences in baseline characteristics were
noted between women who were and were not able to be classi-
fied by pathway (Supplementary Table 4, available online). The
effect estimates for HT use in both the adenoma-carcinoma and
alternate pathways were similar to that seen for HT overall (ad-
enoma-carcinoma OR¼ 0.63, 95% CI¼ 0.55 to 0.73; alternate
OR¼ 0.61, 95% CI¼ 0.51 to 0.72). However, the effect estimate
was attenuated and no longer statistically significant for tumors
that arose via the serrated pathway (OR¼ 0.81, 95% CI¼ 0.66 to
1.01; Phet vs adenoma-carcinoma ¼ .04). This difference was not
consistent across HT formulation: for estrogen-only formula-
tions, ever use was statistically significantly inversely associ-
ated with all 3 pathways (adenoma-carcinoma OR¼ 0.71, 95%
CI¼ 0.57 to 0.88; alternate OR¼ 0.60, 95% CI¼ 0.47 to 0.77;
Figure 2. Association between postmenopausal hormone therapy (HT) use and colorectal cancer (CRC), overall and formulation specific. A-C ¼ adenoma-carcinoma;
CI ¼ confidence interval; CIMP ¼ CpG island methylator phenotype; CRC ¼ colorectal cancer; MSI ¼microsatellite instability; OR ¼ odds ratio.
*Wald P < 0.05. Wald P values are comparing within-group odds ratios; reference groups are BRAF wild-type, KRAS wild-type, CIMP negative, traditional, distal colon.
†Controls are used as reference for all odds ratios. All odds ratios are adjusted for age, body mass index, smoking status, and first-degree family history of CRC.
‡Formulation-specific data were only available for a subset of women (n ¼ 4483 for estrogen-only; n ¼ 4475 for estrogen plus progestin).
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serrated OR¼ 0.72, 95% CI¼ 0.54 to 0.98), and there was no sta-
tistical difference between pathways. However, for estrogen
plus progestin formulations, ever use was only statistically sig-
nificantly associated with tumors that arose via the adenoma-
carcinoma pathway (OR¼ 0.70, 95% CI¼ 0.55 to 0.91).
Most tumors were located in the proximal colon (47.3%),
with tumors of the distal colon (29.4%) only slightly more com-
mon than rectal tumors (23.3%). Compared with distal colon
(OR¼ 0.57, 95% CI¼ 0.49 to 0.66) and rectal tumors (OR¼ 0.54,
95% CI¼ 0.46 to 0.63), the effect estimate for the association of
HT use and proximal colon tumors was attenuated (OR¼ 0.71,
95% CI¼ 0.62 to 0.80; Phet vs distal ¼ .01). This trend was consis-
tent across HT formulations, although there was no statistical
difference between proximal and distal colon tumors for
estrogen-only formulation (Phet ¼.32).
No substantial changes in results were noted after removing
either the 131 women aged 45 years and younger or the 89 wom-
enwith molecularly defined Lynch syndrome (Supplementary
Tables 5 and 6, available online). Meta-analysis results were
consistent with our pooled main analysis (summary OR¼ 0.64,
95% CI¼ 0.58 to 0.71; Phet ¼.10).
Discussion
In this large pooled study of postmenopausal women, HT use,
regardless of formulation type, was associated with a decreased
risk of CRC, consistent with prior research (11–20). In general,
this inverse association was observed irrespective of MSI, CIMP,
BRAF, or KRAS status. However, when considering all tumor
markers together and grouping cases by common pathways and
tumor location, the association was attenuated for tumors aris-
ing via the serrated pathway and for proximal colon tumors.
Our results do not support the hypothesis that the associa-
tion of HT and CRC differs by the individual tumor markers MSI,
BRAF, and KRAS. Strong inverse associations were observed for
HT use and CRC, regardless of BRAF and KRAS status. Prior stud-
ies found a nearly 20% reduced risk among ever HT users irre-
spective of BRAF and KRAS mutation status, although effect
estimates did not reach statistical significance (22, 23). These
studies had substantially smaller samples sizes than ours, con-
tributing to reduced power to detect difference in effect. We ad-
ditionally observed strong inverse associations for HT use and
both MSI-L/MSS and MSI-H CRC. Prior research is somewhat
conflicting regarding the association of HT and MSI status, with
most studies suggesting an association only among MSI-L/MSS
patients (22, 24, 54). There are many possible explanations for
this discrepancy, including sample size, study design, reference
period used for ascertaining HT use, and panels used to classify
MSI status. Because prior studies have indicated high concor-
dance across MSI panels (41), we suspect the latter had the least
influence.
We found some evidence that the association of HT differs
by CIMP status, with an attenuated effect estimate observed for
CIMP-positive tumors. A previous study had similar findings,
reporting a borderline inverse association among CIMP-
negative tumors and no association for CIMP-positive tumors
(22, 47). This finding should be interpreted with caution because
CIMP is not consistently defined across studies, and CIMP preva-
lence may be affected by detection method and sample quality.
Our results suggest that a comprehensive approach of con-
sidering tumor markers together as pathways may reveal other-
wise nebulous patterns. Our findings indicate that the
association of HT use and CRC was largely driven by tumors
arising via the adenoma-carcinoma and alternate pathway.
These tumors make up the majority of CRC cases, whereas ser-
rated tumors represent about 20%–30% of CRC (1, 3, 8, 55–57).
Serrated tumors, characterized as CIMP-positive, BRAF-mutated,
and KRAS wild-type, tend to behave more aggressively, with
faster progression and poorer prognosis (3, 8, 10, 56, 58–60).
Based on the different biologic behavior, appearance, distribu-
tion of tumor markers, and genetic susceptibility of serrated
tumors, it is plausible that HT may indeed play a lesser role in
their pathogenesis.
We also observed a weaker association for tumors of the
proximal colon, consistent with prior studies (22, 24). There is
evidence that serrated tumors are more likely to develop in the
proximal colon (8, 61, 62), so it is unclear whether these are in-
dependent associations. In our study, most serrated tumors
(n¼ 391) were in the proximal colon. The association of HT use
and proximal tumors was similar (OR¼ 0.68, 95% CI¼ 0.60 to
0.78) after removing serrated tumors from analysis, suggesting
an independent association. However, 43.1% (n¼ 776) of proxi-
mal tumors could not be classified by pathway because of in-
complete tumor marker data, so this analysis is limited. The
proximal and distal colon have different embryologic origins,
microbiomes, and microenvironments (62–66). As such, they ap-
pear to be predisposed to different tumor types. For instance,
proximal colon tumors are more likely to be MSI-H, CIMP-posi-
tive, and mucinous and occur more commonly in women and
older individuals (67–71). Further research is needed to better
elucidate whether differences in the proximal colon make it
less sensitive to the effects of estrogens (ie, fewer receptors, dif-
ferent microbiota), whether precancerous lesions in the proxi-
mal colon are estrogen insensitive based on differences in the
carcinogenic pathway, or some combination of factors.
Our results indicate that both estrogen-only and estrogen
plus progestin formulations reduce CRC risk. In general, effect
estimates were attenuated for estrogen plus progestin formula-
tions compared with estrogen-only formulations, perhaps
reflecting smaller exposure frequencies. However, overall
trends were similar. Two main exceptions were present. First,
whereas estrogen-only and any HT use were associated with
about a 40% reduction in tumors arising via the alternate path-
way, estrogen plus progestin use was not statistically signifi-
cantly associated with these tumors. This may indicate that
alternate pathway tumorigenesis is specifically modified by es-
trogen and not progestin. Likewise, there was a null association
between estrogen plus progestin use and proximal colon
tumors despite a 24%–29% reduction in risk with estrogen-only
or any HT, respectively.
To our knowledge, this is the largest study to assess whether
the association of HT use and CRC differs by individual tumor
markers and location. In addition, it is one of few investigations
that combines multiple tumor markers to evaluate tumor path-
way–specific associations. Some limitations should be consid-
ered in interpreting our results. First, all exposure and
epidemiologic covariate information included in this analysis
was based on self-report, which could lead to exposure misclas-
sification. Second, HT use was assessed only during the refer-
ence period, and detailed information on dose, frequency, and
duration of use was not routinely available. Third, we were not
able to assess endogenous hormones that may reflect age at
menarche, parity, or breast feeding, which may also influence
CRC risk. Fourth, there is some evidence that HT users may be
more likely to undergo CRC screening (72, 73). It is unclear how
this may impact our results because this relationship may be
complicated by differences in sensitivity of screening detection
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for specific CRC subtypes. Temporal trends and regional differ-
ences in screening and HT use may also influence observed
associations. Finally, although this study includes populations
in many locales, the participants were predominantly white,
and therefore, these findings may not be generalizable to other
racial and ethnic groups.
In this large, multisite study we observed a strong inverse
association between HT use and CRC risk, regardless of individ-
ual tumor markers and HT formulation. The decreased risk may
predominantly reflect tumors of the distal colon or rectum and
those arising via the adenoma-carcinoma (traditional) pathway,
because the association was relatively weaker among proximal
colon tumors and those arising via the serrated pathway.
Further investigation into the mechanisms underlying these
differences may add to our understanding of subtype-specific
CRC risk and pathways of tumorigenesis.
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